No Data
Huahao Zhongtian Pharmaceutical-B (02563) has signed a market promotion service agreement and supplemental agreement with Baiyang Zhihe.
Zhixun Finance APP reported that Huahao Zhongtian Medical-B (02563) announced that the company recently signed a market promotion service agreement with Beijing Baiyang Zhihe Medical Achievements Transformation Service Co., Ltd., a wholly-owned subsidiary of Qingdao Baiyang Pharmaceutical Co., Ltd. (a company listed on the GEM of the Shenzhen Stock Exchange, stock code: 301015). According to the market promotion service agreement, the company agrees to grant Baiyang Zhihe exclusive market promotion services for Youti Delong injection solution (trade name: Youtidi) to all medical institutions and pharmaceutical retail enterprises in the People's Republic of China (excluding Hong Kong Special Administrative Region, Macao Special Administrative Region, and Taiwan region).
Huahuan Zhongtian Medicine-B (02563.HK) signed a marketing service agreement and a supplementary agreement with Baiyang Zhihhe.
Huahao Zhongtian Pharmaceuticals-B (02563.HK) announced recently that it has signed a market promotion service agreement with Baiyang Pharmaceuticals (301015.SZ), a wholly-owned subsidiary of Baiyang Pharmaceuticals. According to the market promotion service agreement, the company has agreed to grant Baiyang Zhihe exclusive market promotion services for Yutedelon Injection (commodity name Yutedi) in Mainland China. In addition, the company, its wholly-owned subsidiary Chengdu Huahao Zhongtian, and Baiyang Zhihe have signed a supplementary agreement to the market promotion service agreement. According to the supplementary agreement, all parties agree to authorize Baiyang Zhihe to exclusively and exclusively promote designated products in the specified area in accordance with the market promotion service agreement terms.
[IPO Monthly Report] The heat of the Hong Kong IPO market in October shows no signs of decreasing. Karot super subscription 1346 times, CR Beverage may become the annual "Frozen Capital King".
In September, Midea Group Co., Ltd (00300) raised 35.7 billion yuan, becoming the largest fundraising in the Hong Kong stock market since February 2021, the largest in Asia in the first three quarters of 2024, and the second largest globally in 2024. Charles Li Xiaojia, CEO of HKEX, said: "Recently, the Hong Kong Stock Exchange welcomed the largest new stock listing in Asia and the second largest globally this year. Refinancing activities have also been very active, demonstrating the depth and attractiveness of our market. The number of new stock listing applications further consolidates Hong Kong's position as the preferred new stock fundraising center in Asia. In addition, Alibaba has converted to a dual primary listing and was subsequently included in the Stock Connect."
Hong Kong stocks unusual movement | Hua Hao Zhongtian Pharmaceuticals-B (02563) rose nearly 14% on the second day of listing. The core product You Tidelong Injection has been included in medical insurance.
Huahao Zhongtian Pharmaceutical - B (02563) rose nearly 14% on the second day of listing, as of the time of publication, up 7.21%, trading at 22.3 Hong Kong dollars, with a turnover of 12.9399 million Hong Kong dollars.
After boosting the stock price by 30% with the "routine callback", what supports the market cap of nearly 8 billion Hong Kong dollars for Huahao Zhongtian Pharmaceutical - B (02563)?
In short, the weak profit performance, relying solely on a single core product for research and development, creates a certain degree of uncertainty in the future performance of Huahao Zhongtian Pharmaceutical. In addition, with the poor performance of the synthetic biology sector globally on the secondary market, Huahao Zhongtian Pharmaceutical needs to continuously optimize its fundamentals if it wants to prove itself in the Hong Kong stock market, while strengthening innovation and further enhancing its hematopoietic capacity.
Hong Kong Stocks Extend Losses; Beijing Biostar Pharmaceuticals Soars 30% in Debut
No Data
No Data